Airway Therapeutics, Cincinnati Children's Hospital Medical Center pulmonary news

Cincinnati Children's Hospital granted newco Airway Therapeutics an exclusive, worldwide license to commercialize pulmonary therapy research conducted at the hospital, including preclinical recombinant human surfactant protein D (rhSP-D). Airway will initially focus on developing rhSP-D to prevent bronchopulmonary dysplasia (BPD) and to prevent and treat neonatal respiratory distress syndrome (RDS) in premature infants. The company said it plans to meet with FDA in the next few months to confirm plans to develop rhSP-D in combination with a yet to be determined marketed surfactant, with an IND submission to start Phase III testing slated for 1Q13...